- Compare the specific product and indication, not just the biological pathway.
- Visceral-fat outcomes and general weight loss are different questions.
- A historical approval does not validate every current product or advertised use.
Start with the treatment question
Why is the reader comparing these compounds: a diagnosed endocrine condition, a body-composition question, a sports-performance claim, or an online product listing? The answer determines what evidence is relevant. A clinical result in one condition should not be silently extended to all of those settings.
The comparison should identify the actual formulation and the source of its description. Product-specific prescribing information, historical regulatory records, and exploratory research answer different questions. Reading them as one continuous endorsement makes it easy to overstate what is known.
What the sermorelin record establishes
The FDA's 2013 notice concerning GEREF describes historical sermorelin products for childhood growth-hormone deficiency and diagnostic evaluation. It records their discontinuation and the determination that withdrawal from sale was not for safety or effectiveness reasons. That is a product-specific historical determination, not approval of every currently marketed sermorelin product or every adult wellness claim. [1]
A page should preserve that scope. The phrase previously approved can be informative, but it is incomplete without the product, purpose, and time context. Readers should not have to infer those details from a broad marketing statement.
What the tesamorelin label establishes
The EGRIFTA WR prescribing information identifies tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It explicitly states that the product is not indicated for weight-loss management and notes limitations including unestablished long-term cardiovascular safety. The label also specifies clinical precautions and monitoring considerations, including glucose-related issues. [2]
Those details define the comparison. An outcome involving abdominal fat in that population is not equivalent to demonstrating general obesity treatment or muscle growth in healthy adults. The distinction remains important even when a before-and-after image emphasizes a similar-looking body area.
| Dimension | How to read the comparison |
|---|---|
| Biological pathway | Related signaling does not establish equivalent clinical outcomes |
| Product history | Separate a historical named product from a current listing |
| Population | Identify the patients actually described by the study or label |
| Outcome | Distinguish hormone response, visceral fat, weight, muscle, and function |
| Safety | Use product-specific precautions and appropriate clinical assessment |
Body composition is not one number
A scale reading does not reveal every relevant change in the body. Likewise, a measurement of one fat compartment does not describe all body fat, and a change in lean mass does not automatically establish improved strength. A comparison page should identify the measurement rather than translating all results into the broad phrase body transformation.
When a claim concerns muscle growth, look for an actual muscle or strength outcome in a relevant population. When it concerns abdominal fat, look for the method and the patients studied. A shared visual theme is not a substitute for a matched clinical question.
Why dosage conversion is not a useful shortcut
This page does not provide a conversion between the compounds, an administration schedule, or advice to substitute one for the other. Similar names or pathways do not create a justified interchangeability rule. The product, formulation, clinical question, and monitoring all matter.
A responsible discussion with a qualified clinician begins with the reason treatment is being considered, existing conditions and medicines, the intended outcome, and the evidence relevant to that person. An online comparison can help organize those questions, but it cannot answer them on behalf of an individual.
Evaluate the product claim separately
If a seller cites a label or historical approval, ask whether the cited record refers to the actual product offered. If it cites a study, compare the intervention, population, and endpoint. A laboratory report about a sample is useful only for the questions its methods address; it does not supply clinical evidence for an additional use.
A good comparison can therefore reach a clear conclusion without declaring a universal winner: these are different product and evidence contexts, and the right interpretation depends on the intended question. For a related lesson in model-specific findings, read MOTS-c and exercise. The GHK-Cu comparison shows why similar vocabulary does not make ingredients equivalent.
Selected sources
- FDA (2013). Determination concerning the discontinuation of GEREF (sermorelin acetate). Federal Register.
- EGRIFTA WR (tesamorelin): official prescribing information. DailyMed.
Prepared from these selected sources on 12 November 2026. This is an explainer, not a systematic review of every available study.
For educational purposes, not personal medical advice. These pages do not provide self-injection instructions or personalized treatment schedules. Discuss health decisions with a qualified clinician.